Stevanato Group (NYSE:STVN) today announced a collaboration with Thermo Fisher Scientific (NYSE:TMO) on drug delivery technology.
The partnership aims to bring a fully integrated, on-body delivery system platform for subcutaneous administration to market.
Stevanato Group said the device will be semi-reusable and provide micro-precision basal doses and full-content bolus injections. The company intends for the flexible, customizable platform to administer a wide range of therapies.
Get the full story at our sister site, Drug Delivery Business News.